Core Viewpoint - The phase II clinical trial results of Hepu Pharmaceutical's innovative drug Hepulapide combined with PEG interferon for chronic hepatitis B treatment have shown significant efficacy, meeting the sterilizing cure standards set by AASLD and EASL [1][5]. Company Summary - Hepu Pharmaceutical is preparing to initiate phase III clinical trials for Hepulapide in treating chronic hepatitis B, aiming for market registration to benefit patients globally [3]. - The company has developed Hepulapide, a class 1 innovative drug that blocks HBV from entering the cell nucleus, addressing a critical gap in current hepatitis B treatments [4]. Industry Summary - Chronic hepatitis B, caused by HBV, is a highly prevalent infectious disease, with approximately 296 million people infected globally as of 2022, including about 89 million in China [3]. - Current treatments for hepatitis B, such as nucleos(t)ide analogs and interferons, do not cure the disease due to the persistence of cccDNA in the cell nucleus, which can reactivate HBV replication [4].
贺普药业：公司在研新药的二期临床试验结果披露 达到行业乙肝治愈最高标准
Zheng Quan Ri Bao·2025-05-10 02:39